Voice disorders induced by bevacizumab administration in an ovarian cancer patient

Kountourakis, P.; Antoniou, George Α.; Papadimitriou, Konstantinos; Vassiliou, V.; Syrigos, Dimitrios; Philippou, M.; Papamichael, D.

doi:10.1016/j.hemonc.2014.06.003

Cited by 4 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparison of case reports of VEGF inhibitor-induced dysphonia. [4][5][6][7][8] Authors ( This patient experienced dysphonia secondary to bevacizumab after three cycles, which falls in the time frame that has been previously described with bevacizumab and other anti-VEGF inhibitors. Bevacizumabinduced dysphonia has been described to occur as early as the first week of treatment up to the third cycle.…”

Section: Discussionmentioning

confidence: 69%

“…9 Dysphonia has been documented with other anti-VEGF agents, such as sunitinib, sorafenib, pazopanib, axitinib, and regorafenib. 4,7,9,10 Here, we present a case of dysphonia without anatomical changes from bevacizumab in a patient with metastatic, platinumrefractory ovarian cancer.…”

Section: Introductionmentioning

confidence: 96%

“…Previous documented case reports related to VEGF inhibitor-induced dysphonia are summarized in Table 1. [4][5][6][7][8] Additionally, reports of bevacizumab-related dysphonia are summarized in Table 2. 9 Dysphonia has been documented with other anti-VEGF agents, such as sunitinib, sorafenib, pazopanib, axitinib, and regorafenib.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bevacizumab-induced dysphonia: A case report with brief review of literature

Lam

Lee

Sharma

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Anti-angiogenic treatment in adjunct with chemotherapy is widely used for the treatment of various cancers. These agents inhibit vascular endothelial growth factor (VEGF) signaling thereby inhibiting tumor proliferation and invasion. Dysphonia, or voice changes, has been documented, but is an underreported side effect of anti-angiogenic agents. We report a case of intermittent dysphonia in a patient with metastatic, platinum-refractory ovarian cancer treated with bevacizumab. Case report A 48-year-old female with high grade mixed type ovarian adenocarcinoma and concurrent left sided breast cancer was transitioned to palliative therapy with gemcitabine-bevacizumab for her ovarian cancer. At a follow-up visit after three cycles of the new therapy, the patient complained of intermittent changes in her voice, describing periods of hoarseness or softness in her voice after the chemotherapy—sometimes to the point that her voice was inaudible. Management and outcome: A new pelvic thrombus was discovered upon assessment of the patient’s disease. Bevacizumab was held and she was referred to ear, nose, and throat evaluation for dysphonia. Laryngoscopic examination showed normal vocal cord, with normal movements and no lesion or necrosis. During subsequent follow-up, the patient reported improvement in her voice with no additional dysphonia. Discussion Vocal adverse effects of anti-VEGF agents have been documented in landmark trials and case reports; however, clinicians are often unaware of this rare side effect. Although VEGF-induced dysphonia may be rare and may not impede the patient’s quality of life in some cases, it is critical to acknowledge and not underestimate this adverse effect.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Bevacizumab-induced dysphonia: A case report with brief review of literature

Lam

Lee

Sharma

et al. 2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…It has been used to reduce the vascular supply to tumors in advanced lung, renal, and colorectal cancer . Recently, accounts have been published of patients developing hoarseness and white membranous/plaque‐like lesions of the VFs soon after beginning bevacizumab for cancer treatment . These plaques were ultimately diagnosed as VF necrosis and hypothesized to be related to high expression of VEGF receptors 2/3 in glottic capillaries, yielding increased sensitivity to VEGF inhibition .…”

Section: Discussionmentioning

confidence: 99%

“…Due to their binding specificity, MAbs are capable of enhancing or suppressing the immune system, which is most likely the cause of the adverse effects associated with these drugs . Systemic treatment with bevacizumab previously has been reported to be associated with VF lesions . This report aims to describe the previously unreported association between treatment with the monoclonal antibody alirocumab and the development of inflammatory VF lesions.…”

Section: Introductionmentioning

confidence: 97%

Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report

et al. 2016

View full text Add to dashboard Cite

Therapeutic monocolonal antibodies (MAbs) are a new, rapidly growing class of medications that frequently have poorly characterized side-effect profiles. We present a patient who developed inflammatory lesions of the vocal folds in temporal relation to the initiation of alirocumab. Lesions of the vocal folds represent a previously unreported adverse effect of alirocumab therapy, making it the second MAb documented with such a side effect. The potential laryngeal effects of alirocumab specifically, and of MAbs more broadly, warrant investigation. Laryngoscope, 127:1652-1654, 2017.

show abstract

Bevacizumab

2015

Reactions Weekly

View full text Add to dashboard Cite

Voice disorders induced by bevacizumab administration in an ovarian cancer patient

Cited by 4 publications

References 4 publications

Bevacizumab-induced dysphonia: A case report with brief review of literature

Bevacizumab-induced dysphonia: A case report with brief review of literature

Association of alirocumab therapy with inflammatory lesions of the vocal folds: A case report

Bevacizumab

Contact Info

Product

Resources

About